10

Loading video...

Daniella Gray

By Daniella Gray

Reporter

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


Cancer cells have a frustrating ability to adapt when treatment tries to kill them.

Now, researchers have identified a drug combination that could potentially exploit the very survival mechanisms tumors develop to escape therapy.

In a new study, published in Cancer Research, researchers at The University of Texas MD Anderson Cancer Center investigated how breast cancer cells change under prolonged treatment pressure, with the aim of finding vulnerabilities that emerge as the cells become resistant.

Read More on Health

An illustration of therapeutic antibodies attacking cancer cells.

...

Their approach identified two targets, PARP and SHP2, and blocking both produced particularly striking results in preclinical models, including near-complete tumor regression in one breast cancer model.

"What surprised us most was the strongest responses in breast cancer models with intact immune systems, which more closely mimic human disease," co-author Anil Korkut, Ph.D., associate professor of Bioinformatics and Computational Biology, told Newsweek.

"We believe SHP2 inhibition creates stress in cancer cells leading to DNA damage, making them more vulnerable to targeting DNA repair proteins such as PARP," he said.

The researchers used a computational method called TargetScore to analyze changes in proteins and signaling networks as cancer cells adapted to treatment.

Unlike approaches that primarily look for genetic mutations already present in tumors, TargetScore was designed to identify biological changes that appear in response to therapy.

The team focused on resistance to inhibitors of MCL1, a protein that helps cancer cells avoid programmed cell death or apoptosis.

After exposing breast cancer cells to treatment for as long as four months, they found resistant cells were increasingly reliant on pathways involved in cell growth and DNA repair.

Korkut said the findings point to a potentially broader strategy of deliberately creating stress within cancer cells, forcing them to activate compensatory survival mechanisms that can then be targeted.

"We could examine if we are able to induce cellular stress with one agent to force cancer cells to activate compensatory mechanisms to adapt," he explained. "Previous studies from our collaborator, Gordon Mills's laboratory, show that cancer cells become overly dependent on these signals and that targeting them may be a promising strategy."

Researchers are also investigating whether the immune system contributes to the response. Korkut said previous work found PARP inhibition can induce DNA damage and subsequent immune activation, while adding SHP2 inhibition could further amplify that response, potentially opening the door to combinations involving immunotherapy.

When PARP and SHP2 inhibition were tested together across several breast cancer cell models, researchers found additive to synergistic effects.

That provided researchers with a potential new weakness.

One of the most notable results emerged in mice with BRCA1-deficient breast tumors.

Tumors treated with the combination underwent near-complete regression by day 35.

Three of nine animals remained in complete remission beyond 150 days, while median survival reached 239 days in the combination group during a 400-day follow-up.

Dr. Tiffany Troso-Sandoval, a board-certified medical oncologist who spent 25 years treating women with breast and gynecologic cancers at Memorial Sloan Kettering Cancer Center, called the results "exciting," but told Newsweek that that they came from mice and are "not directly applicable to humans yet."

She explained that resistant cancer cells had increased both their growth signaling and DNA-repair mechanisms.

"The SHP2 inhibitor cuts off the growth signals," Troso-Sandoval said. "The PARP inhibitor blocks DNA repair, a weak spot in BRCA1 cancers."

Researchers are also investigating whether the strategy could work in early-stage breast cancer or other cancer types with similar biological characteristics.

"It’s important to note that this is still preclinical, but these mechanistic studies are fundamental to and provide a strong rationale for further clinical investigation that can, hopefully, help patients in the future," Korkut said.

Reference

Augustin Luna, Heping Wang, Lin Wang, Zeynep Dereli, Kang Jin Jeong, Gonghong Yan, Sharad Awasthi, Dong Zhang, Cameron J. Wells, Xubin Li, Ozgun Babur, Nidhi Sahni, Chris Sander, Gerburg M. Wulf, Gordon B. Mills, Anil Korkut; Co-targeting PARP and SHP2 Overcomes Resistance to Apoptosis and Induces Durable Responses in Breast Cancer. Cancer Res 2026; https://doi.org/10.1158/0008-5472.CAN-25-0799

Contact Newsweek editors on this story: Kara Dolman and Paul Donnelley.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines